Visiopharm Diagnostic Packages IVD

CE-IVD

AI-driven precision pathology could improve diagnostic accuracy for biomarker evaluation. Visiopharm’s diagnostic APPs (Application Protocol Package) have been developed in close collaboration with pathologists and are validated and certified under IVDR*.

The APP’s robust and integrated workflow allows the analysis of scanned whole slide images with high accuracy and speed without manual interaction until pathologists' review, delivering objective decision support to the pathologist for clinical biomarker scoring.

Visiopharm’s APPs are available through Agilent as the Visiopharm Diagnostic Package.

* Prostate APP by DeepBio is IVDD

Digital Pathology Apps

Features

Gain confidence in scoring biomarker slides for tissue diagnostics
Validated and IVDR-certified APPs (Prostate APP by DeepBio is IVDD) deliver diagnostic decision support for your review
Fully automated biomarker evaluation integrated into your workflow
Quality-first mindset throughout the entire tissue diagnostics ecosystem
Applications include: PD-L1 for NSCLC, ER, PR, Ki-67, and HER2 for breast cancer, metastasis detection in H&E-stained lymph nodes for breast and colon cancer, Gleason scoring for prostate cancer, invasive tumor detection and hot spot detection

How It Works

Featured References

Product Description References: 1. van Diest, P. J.; Flach, R. N.; van Dooijeweert, C.; et al. Pros and Cons of Artificial Intelligence Implementation in Diagnostic Pathology. Histopathology 2024, 84 (6), 924-934. doi:10.1111/his.15153.

Featured

Visiopharm Diagnostic Packages IVD

Product Details

Digital Pathology Brochure

1. van Diest, P. J.; Flach, R. N.; van Dooijeweert, C.; et al. Pros and Cons of Artificial Intelligence Implementation in Diagnostic Pathology. Histopathology 2024, 84 (6), 924-934. doi:10.1111/his.15153.